NBC Securities Inc. Invests $105,000 in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

NBC Securities Inc. purchased a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 980 shares of the medical equipment provider’s stock, valued at approximately $105,000.

Several other large investors have also recently added to or reduced their stakes in the company. Wesbanco Bank Inc. boosted its holdings in shares of Zimmer Biomet by 2.5% in the 3rd quarter. Wesbanco Bank Inc. now owns 20,411 shares of the medical equipment provider’s stock valued at $2,203,000 after buying an additional 489 shares during the period. CX Institutional acquired a new position in Zimmer Biomet in the third quarter valued at approximately $93,000. Wedge Capital Management L L P NC grew its holdings in shares of Zimmer Biomet by 14.9% during the third quarter. Wedge Capital Management L L P NC now owns 104,232 shares of the medical equipment provider’s stock valued at $11,252,000 after purchasing an additional 13,497 shares during the last quarter. Paladin Wealth LLC bought a new position in shares of Zimmer Biomet during the third quarter valued at approximately $538,000. Finally, Thomasville National Bank raised its position in shares of Zimmer Biomet by 5.6% during the 3rd quarter. Thomasville National Bank now owns 95,410 shares of the medical equipment provider’s stock worth $10,300,000 after purchasing an additional 5,085 shares during the period. 88.89% of the stock is currently owned by institutional investors.

Zimmer Biomet Stock Up 1.3 %

ZBH stock opened at $106.31 on Monday. The firm has a market cap of $21.87 billion, a PE ratio of 23.01, a P/E/G ratio of 1.95 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a 12 month low of $101.47 and a 12 month high of $133.90. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.29 and a quick ratio of 0.63. The firm has a 50 day simple moving average of $108.11 and a 200 day simple moving average of $112.19.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Wednesday, August 7th. The medical equipment provider reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.99 by $0.02. The company had revenue of $1.94 billion for the quarter, compared to analysts’ expectations of $1.94 billion. Zimmer Biomet had a return on equity of 12.86% and a net margin of 13.25%. The firm’s revenue was up 3.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.82 earnings per share. Equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 7.97 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be given a $0.24 dividend. The ex-dividend date is Monday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.90%. Zimmer Biomet’s dividend payout ratio (DPR) is 20.78%.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. BTIG Research lowered their price objective on Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating for the company in a research note on Thursday, October 3rd. Evercore ISI dropped their price objective on shares of Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating on the stock in a report on Tuesday, October 1st. Citigroup cut their price objective on shares of Zimmer Biomet from $134.00 to $120.00 and set a “neutral” rating on the stock in a research report on Wednesday, July 10th. TD Cowen decreased their target price on shares of Zimmer Biomet from $143.00 to $119.00 and set a “hold” rating for the company in a research report on Friday, September 6th. Finally, JPMorgan Chase & Co. cut their price target on Zimmer Biomet from $125.00 to $120.00 and set a “neutral” rating on the stock in a report on Monday, September 16th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $123.94.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.